KNSA - Kiniksa Pharmaceuticals International, plc
About Kiniksa Pharmaceuticals International, plc (https://www.kiniksa.com)
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Sanj K. Patel | Chief Executive Officer & Chairman of the Board | 1969 | $2,241,194 USD |
| Ross Michael Moat | Executive VP, COO & Principal Operating Officer | 1980 | $1,197,373 USD |
| John F. Paolini | Executive Vice President & Chief Medical Officer | 1965 | $1,130,027 USD |
| Eben Tessari | Consultant | 1982 | $1,125,603 USD |
| Mark Ragosa | Executive VP & CFO | 1974 | $1,083,500 USD |
| Aaron Young | Chief Intellectual Property Officer | – | – |
| Douglas Barry | Senior Vice President, Chief Legal Officer & Secretary | – | – |
| Jonathan Kirshenbaum | Investor Relations Officer | – | – |
| Joseph Pirrello | Chief Business Officer | – | – |
| Martina Struck | Senior VP & Chief Regulatory Officer | – | – |
| Mei Jang | Senior VP & Chief Technical Officer | – | – |
| Michael R. Megna | Senior Vice President & Chief Accounting Officer | 1971 | – |